## ZBH: Zimmer Biomet Holdings, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.94 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($87.77)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 9
- **Sentiment:** Neutral (Bullish: 2, Bearish: 1)

**1. Zimmer Biomet, OneStep Collaborate to Provide Enhanced Mobility Data to Patients and Surgeons to Help Improve Joint Procedure Recovery**
- Source: PR Newswire | 20251216T123208 | Bullish | Relevance: 100%
- Zimmer Biomet and OneStep have announced an exclusive collaboration to integrate OneStep's mobility intelligence technology into Zimmer Biomet's mymobility® Care Management Platform. This partnership aims to provide enhanced mobility data to patients and surgeons, improving recovery tracking and patient engagement following joint replacement surgery. The integration will allow users to access objective insights on their recovery using their smartphones, further strengthening Zimmer Biomet's connected care strategy.

**2. Zimmer Biomet (ZBH) Partners with OneStep to Enhance Post-Surgery Mobility Tracking**
- Source: GuruFocus | 20251216T132826 | Bullish | Relevance: 100%
- Zimmer Biomet Holdings, Inc. (ZBH) has partnered with OneStep to integrate advanced mobility data into its mymobility Care Management Platform, aiming to improve post-surgery orthopedic care. This collaboration will provide surgeons with comprehensive patient recovery data and empower patients with real-time insights via their smartphones. Despite strong financial health and profitability, the company's Altman Z-Score indicates potential financial stress, which investors should monitor.

**3. Zimmer Biomet partners with OneStep to enhance mobility tracking By Investing.com**
- Source: Investing.com Australia | 20251216T125509 | Somewhat-Bullish | Relevance: 100%
- Zimmer Biomet Holdings, Inc. has announced an exclusive partnership with OneStep to integrate mobility intelligence technology into its mymobility Care Management Platform. This collaboration will allow surgeons to remotely track patients' post-joint replacement recovery using smartphone technology, leveraging OneStep’s FDA-listed gait and mobility analytics. Despite a year-to-date share decline, Zimmer Biomet maintains strong financial fundamentals, including a healthy current ratio and impressive gross profit margins, with management actively buying back shares and consistently paying dividends.

**4. Baird downgrades Zimmer Biomet stock rating to Neutral on market share concerns**
- Source: Investing.com UK | 20251216T094638 | Somewhat-Bearish | Relevance: 100%
- Baird has downgraded Zimmer Biomet's stock rating from Outperform to Neutral and reduced its price target due to concerns about the company's market share in hip and knee replacement markets, despite good product uptake. The downgrade reflects Zimmer Biomet's struggle to keep pace with competitors like Stryker's MAKO robotic system and downward revisions in analyst earnings expectations. This comes amidst recent FDA clearance for Zimmer Biomet's enhanced knee surgery robot, ROSA Knee with OptimiZe, and mixed third-quarter results that fell short of guidance.

**5. Zimmer Biomet partners with OneStep to enhance mobility tracking**
- Source: Investing.com India | 20251216T131826 | Somewhat-Bullish | Relevance: 98%
- Zimmer Biomet has announced an exclusive collaboration with OneStep to integrate mobility intelligence technology into its mymobility Care Management Platform for joint replacement patients. This partnership will allow surgeons to remotely track patient recovery using smartphone technology, leveraging OneStep’s FDA-listed gait and mobility analytics. The collaboration aims to enhance patient engagement and functional outcomes, supported by Zimmer Biomet's strong financial fundamentals and a broader connected care strategy.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | Citigroup | $94 | $98 | -4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | Citigroup | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 9 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 57.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (+0.2%)
- Dodge & Cox Inc.: 11.7% (+5.1%)
- Blackrock Inc.: 8.1% (+0.2%)
- Price (T.Rowe) Assoc: 7.6% (+1.9%)
- State Street Corpora: 4.4% (-1.3%)

### Key Risks

1. Long-term trend broken: trading 6.2% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.94 indicates undervaluation relative to growth. Forward P/E 10.9x stretched relative to 4% growth. Balance sheet: strong liquidity (2.4x). Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $18.3B |
| Beta | 0.61 |
| 52W Range | $85.33 - $114.44 |
| Short Interest | 4.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.94 |
| Forward P/E | 10.9 |
| Current P/E | 11.3 |
| YoY Growth | 4.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -2.2% to -0.3% (+2.0% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.3pp (needs >4.0% for momentum thesis). MRS_5 turning positive (1.6%) - potential reversal signal. Below SMA200 (0.94x), long-term trend not supportive. RSI neutral at 46. Elevated volume (1.3x 20MA), institutional activity likely. OFD pattern: +SBN (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.26% (CS: 33) | Neutral |
| RSI_14 | 46.0 | Neutral |
| MACD Histogram | 0.02 | Bullish |
| vs SMA20 | 0.995x | Below |
| vs SMA50 | 0.968x | Below |
| vs SMA200 | 0.938x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $92.43
- **Stop Loss:** $87.77 (5.0% risk)
- **Target:** $101.75 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 257
- **Position Value:** $23,754.51
- **Portfolio %:** 23.75%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-05 (Est: $2.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.87 | $1.90 | +1.8% |
| 2025Q2 | $1.98 | $2.07 | +4.8% |
| 2025Q1 | $1.77 | $1.81 | +2.3% |
| 2024Q4 | $2.29 | $2.31 | +0.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*